Suppr超能文献

多重疾病与催眠药和抗焦虑药的使用:冰岛初级医疗保健的横断面研究与随访研究

Multimorbidity and use of hypnotic and anxiolytic drugs: cross-sectional and follow-up study in primary healthcare in Iceland.

作者信息

Linnet Kristjan, Gudmundsson Larus S, Birgisdottir Frida G, Sigurdsson Emil L, Johannsson Magnus, Tomasdottir Margret O, Sigurdsson Johann A

机构信息

Centre of Development, Primary Health Care of the Capital Area, Reykjavik, Iceland.

Clinical Quality and Services, Directorate of Health, Reykjavik, Iceland.

出版信息

BMC Fam Pract. 2016 Jun 6;17:69. doi: 10.1186/s12875-016-0469-0.

Abstract

BACKGROUND

The prevalence of multimorbidity is increasing worldwide, presumably leading to an increased use of medicines. During the last decades the use of hypnotic and anxiolytic benzodiazepine derivatives and related drugs has increased dramatically. These drugs are frequently prescribed for people with a sleep disorder often merely designated as "insomnia" in the medical records and lacking a clear connection with the roots of the patients' problems. Our aim was to analyse the prevalence of multimorbidity in primary healthcare in Iceland, while concurrently investigating a possible association with the prevalence and incidence of hypnotic/anxiolytic prescriptions, short-term versus chronic use.

METHODS

Data were retrieved from a comprehensive database of medical records from primary healthcare in Iceland to find multimorbid patients and prescriptions for hypnotics and anxiolytics, linking diagnoses (ICD-10) and prescriptions (2009-2012) to examine a possible association. Nearly 222,000 patients, 83 % being local residents in the capital area, who contacted 16 healthcare centres served in total by 140 general practitioners, were set as a reference to find the prevalence of multimorbidity as well as the prevalence and incidence of hypnotic/anxiolytic prescriptions.

RESULTS

The prevalence of multimorbidity in the primary care population was 35 %, lowest in the young, increasing with age up to the 80+ group where it dropped somewhat. The prevalence of hypnotic/anxiolytic prescriptions was 13.9 %. The incidence rate was 19.4 per 1000 persons per year in 2011, and 85 % of the patients prescribed hypnotics/anxiolytics were multimorbid. Compared to patients without multimorbidity, multimorbid patients were far more likely to be prescribed a hypnotic and/or an anxiolytic, OR = 14.9 (95 % CI = 14.4-15.4).

CONCLUSIONS

Patients with multiple chronic conditions are common in the primary care setting, and prevalence and incidence of hypnotic/anxiolytic prescriptions are high. Solely explaining use of these drugs by linear thinking, i.e. that "insomnia" leads to their prescription is probably simplistic, since the majority of patients prescribed these drugs are multimorbid having several chronic conditions which could lead to sleeping problems. However, multimorbidity as such is not an indication for hypnotics, and doctors should be urged to greater caution in their prescribing, bearing in mind non-pharmacological therapy options.

摘要

背景

全球范围内,多种疾病并存的情况日益普遍,这可能导致药物使用增加。在过去几十年中,催眠和抗焦虑苯二氮卓衍生物及相关药物的使用急剧增加。这些药物经常被开给患有睡眠障碍的人,而在医疗记录中这些睡眠障碍通常仅被称为“失眠”,且与患者问题的根源缺乏明确关联。我们的目的是分析冰岛初级医疗保健中多种疾病并存的患病率,同时调查其与催眠/抗焦虑药物处方的患病率和发病率、短期使用与长期使用之间可能存在的关联。

方法

从冰岛初级医疗保健的综合医疗记录数据库中检索数据,以找出患有多种疾病的患者以及催眠药和抗焦虑药的处方,将诊断(国际疾病分类第十版,ICD - 10)和处方(2009 - 2012年)相联系,以检查可能存在的关联。将近22.2万名患者(其中83%是首都地区的当地居民)联系了由140名全科医生服务的16个医疗中心,以此作为参考来确定多种疾病并存的患病率以及催眠/抗焦虑药物处方的患病率和发病率。

结果

初级保健人群中多种疾病并存的患病率为35%,在年轻人中最低,随年龄增长而上升,在80岁及以上人群中略有下降。催眠/抗焦虑药物处方的患病率为13.9%。2011年的发病率为每1000人每年19.4例,开具催眠药/抗焦虑药的患者中有85%患有多种疾病。与未患多种疾病的患者相比,患多种疾病的患者更有可能被开具催眠药和/或抗焦虑药,比值比(OR)= 14.9(95%置信区间 = 14.4 - 15.4)。

结论

患有多种慢性病的患者在初级保健环境中很常见,催眠/抗焦虑药物处方的患病率和发病率都很高。仅用线性思维来解释这些药物的使用,即认为“失眠”导致了它们的处方,可能过于简单,因为大多数开具这些药物的患者患有多种慢性病,这些疾病可能导致睡眠问题。然而,多种疾病并存本身并不是使用催眠药的指征,应敦促医生在开药时更加谨慎,同时要考虑非药物治疗方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde2/4896036/976fd266cedf/12875_2016_469_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验